Introduction {#s1}
============

Pneumonia is the leading cause of death due to infection [@pone.0070142-Hoyert1], [@pone.0070142-Lin1], and it accounts for more than 1 million hospitalizations annually in the United States at an estimated cost of 12.2 billion [@pone.0070142-Colice1]. In Taiwan, about 160,000 are hospitalized annually for treatment of pneumonia [@pone.0070142-Lin1]. Patients with schizophrenia who develop pneumonia are more likely to have poorer outcomes requiring more frequent ventilator treatment and carrying greater risk of acute respiratory failure than in the general population [@pone.0070142-Chen1]. Furthermore, compared with the general population, patients with schizophrenia have excessive mortality attributable to natural causes [@pone.0070142-Chen2]. Thus, as a basis for prevention, to recognize the risk factors associated with short-term mortality among schizophrenia patients with pneumonia is crucial for preventing premature deaths. We found limited paucity of data regarding these issues in the literature.

Short-term mortality among the schizophrenic patients with pneumonia can result from pre-existing comorbid physical illnesses [@pone.0070142-Knol1], [@pone.0070142-Trifiro1], [@pone.0070142-Kuo1], incident physical complications developing after the pneumonia [@pone.0070142-CorralesMedina1], [@pone.0070142-Lepper1], drugs potentially associated with the development of pneumonia (such as antipsychotic drugs) [@pone.0070142-Kuo1], [@pone.0070142-Yang1], and quality of care [@pone.0070142-Chen1], [@pone.0070142-Welte1].

Pre-existing physical comorbidities before the development of pneumonia could precipitate short-term death [@pone.0070142-Yende1], and recent studies reported incident physical illnesses after pneumonia are associated with short-term mortality [@pone.0070142-CorralesMedina1], [@pone.0070142-Lepper1], [@pone.0070142-CorralesMedina2]. A recent meta-analysis [@pone.0070142-CorralesMedina2] reported major cardiac complications occurred in a substantial proportion (17.7%) of patients with community-acquired pneumonia, including incident heart failure, acute coronary syndromes, and arrhythmias. Furthermore, incident cardiac complications are common in patients with community-acquired pneumonia and are associated with increased short-term mortality [@pone.0070142-CorralesMedina1]. Additionally, a recent study [@pone.0070142-Lepper1] reported that serum glucose levels on admission to the hospital are predictive of short-term mortality in patients with community acquired pneumonia without pre-existing diabetes. Whether the pre-existing or incident physical illnesses after pneumonia predict short-term mortality among schizophrenic patients with pneumonia is still undetermined.

An emerging body of literature shows the association between antipsychotic drugs and the development of pneumonia in the elderly population [@pone.0070142-Knol1], [@pone.0070142-Trifiro1], in patients with schizophrenia [@pone.0070142-Kuo1], and in bipolar patients [@pone.0070142-Yang1]. Several individual antipsychotics (such as clozapine, olanzapine, and quetiapine) are associated with incident pneumonia [@pone.0070142-Kuo1], [@pone.0070142-Yang1]. Nonetheless, rare studies focused on the association between the antipsychotic drugs and short-term mortality.

We explored the risk factors associated with short-term mortality in a nested case-control study derived from a large, nationwide schizophrenia cohort hospitalized for pneumonia in Taiwan. We focused on the potential factors before and during hospitalization, including the drugs used, pre-existing and incident physical illnesses, and the characteristics of hospital care relative to the risk of short-term mortality, with the outlook of preventing premature deaths.

Methods {#s2}
=======

Data Source {#s2a}
-----------

The sampling cohort was obtained from the National Health Insurance (NHI) Research Database in Taiwan. The NHI program was launched on March 1, 1995 and contains registration files and original claims data for reimbursement. There are currently more than 23 million enrollees in the program representing 99.6% of Taiwan's population in 2011 [@pone.0070142-Yang1]. In 1996, the National Health Research Institute in Taiwan established the NHI Research Database.

Ethics Statement {#s2b}
----------------

Individual identification is decoded for protection of confidentiality and all investigators signed an agreement guaranteeing patient confidentiality before using the database. This study was approved by the Institutional Review Board of the Committee on Human Subjects of Taipei City Hospital.

Schizophrenia Cohort with Pneumonia as the Study Cohort {#s2c}
-------------------------------------------------------

The schizophrenia cohort is described in detail in our previous study [@pone.0070142-Kuo1] and is briefly summarized here. The nationwide Psychiatric Inpatient Medical Claims database, a subset of the NHI research database, comprises a cohort of patients hospitalized for any psychiatric disorder (ICD-9-CM codes 290.xx to 319.xx) between 1996 and 2008 (N = 187,117), was used in this study.

We selected patients with at least one psychiatric admission between 2000 and 2008 but no psychiatric admissions between 1996 and 1999 (N = 125,225) from the Psychiatric Inpatient Medical Claims database. The inclusion criteria for the study subjects were at least one discharge diagnosis of schizophrenia (ICD-9-CM code 295.xx) and age at first admission of 18 to 65 years (N = 35,627). If a member of the schizophrenia cohort had a discharge diagnosis of pneumonia (ICD-9-CM codes 480.xx--486.xx and 507.xx) after their first admission, then they were included in this study (n = 1,741), and this group was defined as the study cohort. All of their medical records during 1999 and 2008 were retrieved [@pone.0070142-Gau1]. A flow diagram of this study is provided in the supplementary material ([Figure S1 in File S1](#pone.0070142.s001){ref-type="supplementary-material"}).

Short-Term Mortality Cases and their Controls {#s2d}
---------------------------------------------

Among the study cohort, a total of 141 subjects died during their hospitalizations, or died shortly (within 30 days) after their discharges, as identified in the Registry for Beneficiaries database [@pone.0070142-Tung1]; these subjects were defined as the cases with short-term mortality.

The date of pneumonia hospitalization was defined as the baseline and the date of mortality was defined as the index date ([Figure 1](#pone-0070142-g001){ref-type="fig"}). Four controls or fewer (i.e., nonfatal pneumonia subjects) were randomly selected for each case from the cohort by risk set sampling, matching sex, age (within 5 years), and date of first psychiatric admission (within 1 year). Controls were assigned the same index date as their corresponding case. Finally, this study included a total of 128 case-control pairs (i.e., 128 cases and 468 controls) due to unavailability of controls for 13 cases.

![Overview for Study design.](pone.0070142.g001){#pone-0070142-g001}

Drugs Exposure and Physical Illnesses {#s2e}
-------------------------------------

We obtained the medication histories of subjects for two periods ([Figure 1](#pone-0070142-g001){ref-type="fig"}): the period within 30 days before baseline (ie., the date of pneumonia requiring hospitalization) was defined as pre-hospitalization period for drug use. The medications included antipsychotic drugs and drugs administered for other medical conditions. Drugs were classified according to the Anatomical Therapeutic Chemical classification system [@pone.0070142-WHOCollaboratingCentreforDrugStatisticMethodology1]. The most common second-generation antipsychotics used by schizophrenic patients in Taiwan were selected, including clozapine, olanzapine, quetiapine, zotepine, risperidone, and amisulpride. First-generation antipsychotics included chlorpromazine, haloperidol, and sulpiride.

Physical illnesses were identified according to three definitions ([Figure 1](#pone-0070142-g001){ref-type="fig"}): pre-existing, incident, and prevalent illnesses. Pre-existing physical illnesses were an illness present within 180 days before the baseline date. Incident physical illness was an illness newly appearing after the baseline date. Those who had pre-existing or incident physical illnesses were defined as having prevalent physical illnesses.

Physical illnesses including cardiovascular disease (arrhythmia, heart failure, coronary heart failure, acute myocardial infarction, and hypertension), diabetes mellitus, cerebrovascular disease, chronic hepatic disease, cancer, asthma, upper respiratory tract infection, and delirium were studied for the association of risk with short-term mortality.

Potential Risk Factors {#s2f}
----------------------

Age and gender were controlled by the matching process of the study design. The Charlson comorbidity score [@pone.0070142-Quan1], [@pone.0070142-Quail1], which is the sum of the weighted scores of 31 comorbid conditions, at first psychiatric admission was used for adjustment of potential confounders in the analyses. The number of psychiatric hospitalizations within 180 days before the baseline was one of the covariates adjusted.

Statistical Analysis {#s2g}
--------------------

The crude incidence of short-term mortality was calculated as the number of incident cases divided by the contributed person-years for each individual in the cohort. Group comparisons between cases and controls were performed using univariate conditional logistic regression initially. Covariates with reasonable associations (p\<0.1) were then entered into the final adjusted models. Multivariate regression with stepwise selection was used to estimate the adjusted models of association for short-term mortality.

Depending on the characteristics of drug exposure, physical illnesses, and potential risk factors at different time points during the course of pneumonia, three explanatory models were computed, including a pre-hospitalization model, during-hospitalization model 1, and during-hospitalization model 2. Incident physical illnesses were included in during-hospitalization model 1, while the prevalent illnesses were included in model 2.

Hospital characteristics, ownership, urbanization [@pone.0070142-Liu1], and physician characteristics of age, gender, and specialty were included in during-hospitalization models 1 and 2, and are provided in the supplementary material ([Table S1 in File S1](#pone.0070142.s001){ref-type="supplementary-material"}). Multivariate models were calculated using SAS software, version 9.2 (SAS Institutes Inc., Cary, NC, USA). P values less than 0.01 were considered significant.

Sensitivity Analysis {#s2h}
--------------------

Recent studies [@pone.0070142-Kuo1], [@pone.0070142-Yang1] showed that dose and duration of antipsychotic drugs are associated with increased risk of pneumonia. We conducted a sensitivity analysis for validating the risk of second-generation antipsychotic drugs on short-term mortality based on duration of use and cumulative defined daily dose within 30 days before hospitalization and during hospitalization. The results are provided in the supplementary materials ([Table S2 in File S1](#pone.0070142.s001){ref-type="supplementary-material"}, [Table S3 in File S1](#pone.0070142.s001){ref-type="supplementary-material"}).

Results {#s3}
=======

Incidence of Short-term Mortality {#s3a}
---------------------------------

This study included 1741 schizophrenia patients with community-acquired pneumonia requiring hospitalization. Among the 141 cases with short-term mortality, 114 subjects died during hospitalization and 27 subjects died within 30 days after discharge. About 1 in 12 pneumonia patients (141/1741) died shortly after the development of pneumonia. The crude incidence of short-term mortality was calculated as the number of short-term mortality cases divided by the contributed person-years of all subjects (66,838 admission-days) in the cohort. The incidence of short-term mortality was 2.11 cases per 1,000 person-days (95% CI: 1.80--2.50, based on the Poisson distribution).

Demographical and Clinical Characteristics of Cases and Controls {#s3b}
----------------------------------------------------------------

Analysis of demographic characteristics showed that there was no difference between cases and controls in gender, age, or Charlson comorbidity index ([Table 1](#pone-0070142-t001){ref-type="table"}). The mean number of psychiatric hospital admissions among cases was significantly lower than among controls (0.5 vs. 0.7, p = 0.0013).

10.1371/journal.pone.0070142.t001

###### Demographical and Clinical Characteristics of Cases with Short-Term Mortality and Controls Derived from a Nationwide Schizophrenia Cohort with Pneumonia Requiring Hospitalization.

![](pone.0070142.t001){#pone-0070142-t001-1}

  Characteristic N (%)                                                            Cases (n = 128)   Controls (n = 468)   Unadjusted risk ratio[a](#nt101){ref-type="table-fn"}     95% CI
  ------------------------------------------------------------------------------ ----------------- -------------------- ------------------------------------------------------- ------------
  At first psychiatric admission                                                      *n (%)*            *n (%)*                                                                
  Men                                                                                72 (56.3)          275 (58.8)                                --                                 --
  Mean age (SD), years                                                              48.5 (11.0)        48.4 (10.8)                               1.00                            0.89--1.12
  Charlson comorbidity index                                                                                                                                                    
   0--1                                                                              99 (77.3)          344 (73.5)                             Reference                        
   2                                                                                 19 (14.8)          96 (20.5)                                0.65                            0.37--1.14
   ≥3                                                                                10 (7.8)            28 (6.0)                                1.31                            0.60--2.85
                                                                                    *mean (SD)*        *mean (SD)*                                                              
  Number of psychiatric hospital admissionswithin 180 days before the baseline       0.5 (0.7)          0.7 (1.0)                0.61[\*](#nt102){ref-type="table-fn"}           0.46--0.83
  Duration between the baseline and the index date, days                            13.3 (13.0)        11.9 (11.6)                                --                                 --

Estimated using univariate conditional logistic regression;

p\<0.01.

Pre-existing, Incident, and Prevalent Physical Illness {#s3c}
------------------------------------------------------

Univariate analyses ([Table 2](#pone-0070142-t002){ref-type="table"}) showed that rather than controls, cases had higher proportions of pre-existing arrhythmia, cancer, and chronic hepatic disease. Cases had higher proportions of incident physical illnesses only for arrhythmia (6.3% vs. 1.1%, p = 0.0014) and heart failure (4.7% vs. 1.1%, p = 0.0119) than did controls.

10.1371/journal.pone.0070142.t002

###### Distribution of Physical Illnesses among Cases with Short-Term Mortality and Controls.

![](pone.0070142.t002){#pone-0070142-t002-2}

  Characteristics, n (%)         Pre-existing illness[a](#nt103){ref-type="table-fn"}   Incident physical illness[b](#nt104){ref-type="table-fn"}   Prevalent physical illness[c](#nt105){ref-type="table-fn"}                                                                                                                          
  ----------------------------- ------------------------------------------------------ ----------------------------------------------------------- ------------------------------------------------------------ --------- ------------------------------------------ -------- ----------- --------------------------------------------- ---------
  Cardiovascular disease                                                                                                                                                                                                                                                                                                                
  Arrhythmia                                           9 (7.0)                                  8 (1.7)[\*](#nt108){ref-type="table-fn"}                                      \<0.01                             8 (6.3)   5 (1.1)[\*](#nt108){ref-type="table-fn"}   \<0.01   17 (13.3)   13 (2.8)[\*\*](#nt109){ref-type="table-fn"}   \<0.001
  Heart failure                                        6 (4.7)                                                  11 (2.4)                                                        ns                               6 (4.7)   5 (1.1)[+](#nt110){ref-type="table-fn"}    0.0119   12 (9.4)     16 (3.4)[\*](#nt108){ref-type="table-fn"}    \<0.01
  Acute myocardial infarction                          1 (0.8)                                                   1 (0.2)                                                        ns                               2 (1.6)                   1 (0.2)                      ns      3 (2.3)                      2 (0.4)                       ns
  Coronary heart diseases                              8 (6.3)                                                  32 (6.8)                                                        ns                               2 (1.6)                   12 (2.6)                     ns     10 (7.8)                     44 (9.4)                       ns
  Hypertension                                        22 (17.2)                                                 86 (18.4)                                                       ns                               1 (0.8)                   12 (2.6)                     ns     23 (18.0)                    98 (20.9)                      ns
  Cancer                                              20 (15.6)                                21 (4.5)[\*\*](#nt109){ref-type="table-fn"}                                   \<0.001                             7 (5.5)                   15 (3.2)                     ns     27 (21.1)   36 (7.7)[\*\*](#nt109){ref-type="table-fn"}   \<0.001
  Chronic hepatic disease                             20 (15.6)                                 32 (6.8)[\*](#nt108){ref-type="table-fn"}                                     \<0.01                             3 (2.3)                   10 (2.1)                     ns     23 (18.0)    42 (9.0)[\*](#nt108){ref-type="table-fn"}    \<0.01
  Diabetes mellitus                                   22 (17.2)                                                 63 (13.5)                                                       ns                               7 (5.5)                   17 (3.6)                     ns     29 (22.7)                    79 (16.9)                      ns
  Cerebrovascular disease                              7 (5.5)                                                  34 (7.3)                                                        ns                               7 (5.5)                   17 (3.6)                     ns     14 (10.9)                    51 (10.9)                      ns
  Asthma                                               4 (3.1)                                                  19 (4.1)                                                        ns                               1 (0.8)                   5 (1.1)                      ns      5 (3.9)                     24 (5.1)                       ns
  Delirium                                             1 (0.8)                                                   3 (0.6)                                                        ns                                  0                         0                         ns      1 (0.8)                      3 (0.6)                       ns

Pre-existing physical illness: illness present within 180 days before hospitalization.

Incident physical illness: the illness newly appeared after hospitalization.

Prevalent physical illness: pre-existing and incident physical illnesses combined.

Estimated using univariate conditional logistic regression.

ns: not significant (p\>0.01),

p\<0.01,

p\<0.001,

marginal statistical significance.

Prevalent physical illnesses during hospitalization among cases revealed greater proportions of heart failure, arrhythmia, chronic hepatic disease, and cancer than among control cases.

Medication Exposure {#s3d}
-------------------

[Table 3](#pone-0070142-t003){ref-type="table"} summarizes the medication exposure in both the pre-hospitalization and during-hospitalization periods. Pre-hospitalization use of antipsychotic drugs did not differ between cases and controls, except for hypoglycemic drugs, which were used in a higher proportion among cases compared with controls with marginal statistical significance (p = 0.0254).

10.1371/journal.pone.0070142.t003

###### Distribution of Antipsychotics and Other Medications Used in Cases with Short-Term Mortality and Controls.

![](pone.0070142.t003){#pone-0070142-t003-3}

                                                   Pre-Hospitalization Period   During-Hospitalization Period                                                                   
  ----------------------------------------------- ---------------------------- ------------------------------- ---- ----------- ----------------------------------------------- ---------
  **Antipsychotic drugs**                                                                                                                                                       
  Clozapine                                                13 (10.2)                      69 (14.7)             ns    5 (3.9)    75 (16.0)[\*\*](#nt114){ref-type="table-fn"}    \<0.001
  Olanzapine                                                9 (7.0)                       31 (6.6)              ns    3 (2.3)     47 (10.0)[\*](#nt113){ref-type="table-fn"}     \<0.01
  Quetiapine                                               17 (13.3)                      42 (9.0)              ns    6 (4.7)                      37 (7.9)                        ns
  Zotepine                                                  5 (3.9)                       31 (6.6)              ns    4 (3.1)                      33 (7.1)                        ns
  Risperidone                                              23 (18.0)                     105 (22.4)             ns    7 (5.5)    96 (20.5)[\*\*](#nt114){ref-type="table-fn"}    \<0.001
  Amisulpride                                               1 (0.8)                       16 (3.4)              ns    0 (0.0)                      19 (4.1)                        ns
  Chlorpromazine                                            10 (7.8)                      22 (4.7)              ns    4 (3.1)                      28 (6.0)                        ns
  Haloperidol                                              22 (17.2)                      78 (16.7)             ns   19 (14.8)   147 (31.4)[\*\*](#nt114){ref-type="table-fn"}   \<0.001
  Sulpiride                                                14 (10.9)                      73 (15.6)             ns   11 (8.6)                      68 (14.5)                       ns
  **Other drugs**                                                                                                                                                               
  Cardiovascular drugs                                                                                          --                                                                 --
   Antihypertensive drugs                                   4 (3.1)                       22 (4.7)              ns    3 (2.3)                      23 (4.9)                        ns
   Beta blocking agents                                    22 (17.2)                     119 (25.4)             ns   20 (15.6)                    121 (25.9)                       ns
   Calcium channel blockers                                16 (12.5)                      55 (11.8)             ns   29 (22.7)                     85 (18.2)                       ns
   Agents acting on the renin-angiotensinsystem             8 (6.3)                       28 (6.0)              ns    6 (4.7)                      40 (8.6)                        ns
  Lipid modifying agents                                    3 (2.3)                        6 (1.3)              ns    1 (0.8)                       7 (1.5)                        ns
  Hypoglycemic drugs                                       23 (18.0)                      50 (10.7)             ns   44 (34.4)   80 (17.1)[\*\*](#nt114){ref-type="table-fn"}    \<0.001
  Antithrombotic agents                                     12 (9.4)                      37 (7.9)              ns   16 (12.5)                     58 (12.4)                       ns
  Corticosteroids for systemic use                         16 (12.5)                      33 (7.1)              ns   62 (48.4)   126 (26.9)[\*\*](#nt114){ref-type="table-fn"}   \<0.001
  Anti-Parkinson drugs                                     60 (46.9)                     248 (53.0)             ns   27 (21.1)   205 (43.8)[\*\*](#nt114){ref-type="table-fn"}   \<0.001
  Respiratory drugs                                        47 (36.7)                     210 (44.9)             ns   98 (76.6)                    374 (79.9)                       ns
  Benzodiazepines                                          59 (46.1)                     249 (53.2)             ns   64 (50.0)    289 (61.8)[\*](#nt113){ref-type="table-fn"}    \<0.01

Estimated using univariate conditional logistic regression.

ns: not significant (p\>0.01),

p\<0.01,

p\<0.001.

Cases had lesser during-hospitalization use of multiple antipsychotic drugs (including clozapine, olanzapine, risperidone, and haloperidol) than controls. Relative to controls, cases used a greater proportion of hypoglycemic drugs and corticosteroids, while anti-Parkinson drugs and benzodiazepines were used in lower proportions.

Multivariate Regression Model (Pre-hospitalization Model, During-hospitalization Models 1 and 2) {#s3e}
------------------------------------------------------------------------------------------------

In the pre-hospitalization model ([Figure 2](#pone-0070142-g002){ref-type="fig"}), several factors carried significantly increased risks of short-term mortality, specifically pre-existing arrhythmia and cancer, while the number of psychiatric hospital admissions and use of respiratory drugs indicated lower risk.

![Multivariate Conditional Logistic Regression of Risk Factors for Short-Term Mortality among Schizophrenia Patients with Pneumonia Requiring Hospitalization.](pone.0070142.g002){#pone-0070142-g002}

In during-hospitalization model 1, incident arrhythmia (RR = 7.44, p = 0.0038) greatly increased the risk of short-term mortality, while incident heart failure was associated with higher (RR = 5.49, p = 0.0183). Hypoglycemic drug use (RR = 2.32, p = 0.0029) was associated with a higher risk of short-term mortality, while risperidone use was associated with a lower risk.

In during-hospitalization model 2, prevalent physical illnesses including arrhythmia, heart failure, and cancer were associated with increased risk of short-term mortality. Hypoglycemic drug use showed an increased risk of short-term mortality, while the use of risperidone was associated with a lower risk.

Sensitivity Analysis {#s3f}
--------------------

Based on the duration and cumulative dose of pre-hospitalization drug use, the associations between second-generation antipsychotic drugs and risk of short-term mortality are summarized in the supplementary material ([Table S2 in File S1](#pone.0070142.s001){ref-type="supplementary-material"}). After adjustment, the results showed that the second-generation drugs had no association with increased risk of short-term mortality. Furthermore, the duration and dose of during-hospitalization second-generation antipsychotics use did not increase the risk of short-term mortality ([Table S3 in File S1](#pone.0070142.s001){ref-type="supplementary-material"}). These findings provide evidence strengthening the notion that second-generation antipsychotic drugs have no role in causing short-term mortality.

Discussion {#s4}
==========

Strengths {#s4a}
---------

To our knowledge, this is the first nationwide case-control study to investigate the factors associated with short-term mortality in schizophrenia patients with pneumonia requiring hospitalization. This study revealed that a considerable portion of subjects died during their hospitalizations. We believe these patients deserve special clinical attention while hospitalized for pneumonia. By means a nested case-control study that is clear in temporal sequence, this study demonstrated that short-term mortality was associated with cardiac complications, such as arrhythmia and heart failure.

Cardiac Complications {#s4b}
---------------------

Despite the fact that pneumonia [@pone.0070142-CorralesMedina1] is a leading cause of death, little consideration has been given to understanding the contributors to this mortality, especially among schizophrenia patients. Based on chronological order, the pre-hospitalization multivariate model provides clear evidence that pre-existing arrhythmia and cancer are risk factors for subsequent short-term mortality. A recent study [@pone.0070142-CorralesMedina1] reported that pre-existing cardiovascular disease was associated with increased short-term mortality in patients with community-acquired pneumonia. We add to this the evidence of pre-existing arrhythmia before pneumonia, which predicted the short-term mortality.

Three prior studies [@pone.0070142-CorralesMedina1], [@pone.0070142-Musher1], [@pone.0070142-Mandal1] suggested incident cardiac complications following the pneumonia were associated with increased mortality in patients with community-acquired pneumonia, and one of them [@pone.0070142-CorralesMedina1] adjusted for pneumonia severity showing a 1.6-fold risk for short-term mortality when patients had existing incident cardiac complications. Nonetheless, no prior studies showed the specific cardiac complications as predictors for short-term mortality, especially in non-elderly patients with schizophrenia. The present study adds robust evidence to identify incident arrhythmia and incident heart failure as the risk factors for short-term mortality among schizophrenia patients.

Pneumonia can induce several types of acute cardiac events through different mechanisms [@pone.0070142-Musher1], including arrhythmia, congestive heart failure, acute myocardial infarction, and coronary heart disease. This provides possible explanation for the association between acute cardiac events and short-term mortality in pneumonia patients [@pone.0070142-Musher1]. First, arrhythmia and congestive heart failure share similar pathogenesis, including increased myocardial demand for oxygen, lowered blood oxygen levels via ventilation-perfusion mismatch, and suppression of ventricular function by elevated levels of cytokines [@pone.0070142-Musher1], [@pone.0070142-Kumar1]. Second, acute myocardial infarction is the most severe form of coronary heart disease. In this study, we could not prove the association between acute myocardial infarction and short-term mortality, which might be due to the low incidence of acute myocardial infarction among the schizophrenia patients with pneumonia. Coronary heart disease was distributed similarly between the cases and controls and, thus, is unlikely to be a predictor of short-term mortality.

The striking findings of this study demonstrated that specific cardiac complications, i.e., incident arrhythmia or incident heart failure, superimposed on pneumonia resulted in greater harm, especially short-term mortality, which was in line with the first proposed mechanism described above. Given this possible mechanism, incident arrhythmia or incident heart failure, which are pneumonia-related illnesses could be intermediate factors [@pone.0070142-CorralesMedina2] and result in the short-term mortality. The possible mechanism deserves future work for clarification.

This study has few pneumonia cases developed incident physical illness after pneumonia and incident physical illnesses might exist before pneumonia happened with under diagnosis (especially in schizophrenia). Thus, future studies with larger sample size and better detection of incident physical illnesses before pneumonia are needed.

Hypoglycemic Drugs {#s4c}
------------------

One of our major findings was that hypoglycemic drugs used during the hospitalization period were strongly associated with short-term mortality in the multivariate regression analyses. Use of hypoglycemic drugs reflects clinical hyperglycemia requiring treatment. This finding is in line with a recent study [@pone.0070142-Lepper1] that reported serum glucose levels on admission to the hospital can be used to predict death in patients with community-acquired pneumonia without pre-existing diabetes.

One of the limitations of our study was that we were unable to differentiate hyperglycemia during hospitalization into pre-existing hyperglycemia or incident hyperglycemia after the pneumonia. Our study did not show that patients with diabetes had a significantly increased risk of short-term mortality compared with patients without diabetes. Thus, we believe that hyperglycemia instead of diabetes mellitus is a sensitive marker for predicting short-term mortality. Given this possible mechanism [@pone.0070142-McAlister1], patients with hyperglycemia are prone to dehydration secondary to osmotic diuresis and exhibit a variety of perturbations of platelet function and endothelial function, as well as delayed chemotaxis, diminished granulocyte adherence, impaired phagocytosis, and reduced antimicrobial capacity [@pone.0070142-Oliver1], [@pone.0070142-Williams1], [@pone.0070142-McMahon1], which could enhance the risk of mortality.

Antipsychotic Use {#s4d}
-----------------

A recent study [@pone.0070142-Chou1] highlighted that the proportion of days covered with psychiatric medication in a year was positively associated with pneumonia but negatively associated with death. Prior studies [@pone.0070142-Trifiro1], [@pone.0070142-Kuo1], [@pone.0070142-Yang1] have further indicated that antipsychotic drugs contributed the development of pneumonia, especially clozapine and olanzapine [@pone.0070142-Kuo1], [@pone.0070142-Yang1]. Nonetheless, based on multivariate regression, this study found that the use of antipsychotic drugs in both the pre-hospitalization and during-hospitalization periods were not associated with short-term mortality, except the use of risperidone during hospitalization period ([Figure 2](#pone-0070142-g002){ref-type="fig"}). This study has its potential limitation due to protopathic bias [@pone.0070142-Feinstein1], i.e., the assignment of antipsychotics based on the patient's clinical condition. One possible explanation was that during hospitalization, medication for chronic disease usually paused until acute symptoms were relieved. Thus, despite risperidone's significantly negative association with short-term mortality, conservatively, we cannot conclude it has a protective effect against short-term mortality. In contrast, because antipsychotic drugs are associated with a risk of pneumonia, whether the use of antipsychotics during hospitalization should be continued or discontinued, or continued at a low dose to reduce the risk of pneumonia deserves further research. Furthermore, the causes and types of pneumonia were not specified in this study. The direct link between use of antipsychotics and short-term mortality is still awaiting further clarification.

Hospital Care {#s4e}
-------------

Although prior studies [@pone.0070142-Chen1], [@pone.0070142-Welte1], [@pone.0070142-Song1] reported poor care quality was associated with mortality during hospitalization for pneumonia, the characteristics of hospital care were not associated with short-term mortality among schizophrenia patients hospitalized for pneumonia in our study ([Table S1 in File S1](#pone.0070142.s001){ref-type="supplementary-material"}).

Limitations {#s4f}
-----------

This study is limited in several ways. First, our study did not cover data regarding the pneumonia severity index [@pone.0070142-CorralesMedina1] as well as causes and types of pneumonia, which could, along with the protopathic bias, influence the prescribing behavior of doctors. Nonetheless, the estimation of the association between incident physical illnesses and risk of short-term mortality was less biased due to the nature of data being unrelated to protopathic bias.

Second, body weight and laboratory data were unavailable in the claims database. Potential unmeasured confounders or mediators included obesity, neutropenia, and hyperglycemia. We used the hypoglycemic drugs as the surrogate to reflect the clinical condition of hyperglycemia.

Third, the analyses did not include psychiatric severity data obtained from the claims data. Nonetheless, the number of prior psychiatric hospitalizations (a surrogate for severity) was removed in the multivariate analysis, providing evidence that short-term mortality could be independent of psychiatric severity.

Furthermore, a recent study [@pone.0070142-Chou1] demonstrated that incidence and all-cause mortality of pneumonia in patients with schizophrenia were age-dependent and sex-specific. In this study, we used sex and age as matching variables to rule out the potential effects of these two variables and crystallized risk factors for short-term mortality of schizophrenia patients with pneumonia. However, sample selection bias or type I error due to small sample size could not be ruled out and limit the generalization and practicability.

Implications {#s4g}
------------

In summary, our study demonstrates that pre-existing arrhythmia predicts subsequent short-term mortality. Furthermore, incident arrhythmia following pneumonia has an independent impact on short-term mortality, so does incident heart failure. Additionally, hyperglycemia during hospitalization is another risk factor. Antipsychotic drugs with known induction of pneumonia were not associated with risk of mortality. Clinicians must recognize the burden of incident arrhythmia and heart failure among schizophrenia patients with pneumonia and keep clinically vigilant for their timely recognition.
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